Free tool
FAERS Monitor: Eylea
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125387 or its brand name (Eylea, Aflibercept). Reports on generic versions are filed under their own applications.
Reports
30,249
Serious
24,786
82% of reports
Hospitalization
3,966
Death reported
8,878
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death7,876
- visual impairment2,037
- off label use1,631
- blindness1,437
- endophthalmitis1,341
- visual acuity reduced1,236
- drug ineffective1,188
- eye pain1,162
- vision blurred1,149
- product dose omission issue1,106
- blindness unilateral1,048
- blindness transient977
- eye inflammation924
- eye haemorrhage798
- vitreous floaters780
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 5 |
| 2008 | 2 |
| 2009 | 11 |
| 2010 | 45 |
| 2011 | 27 |
| 2012 | 172 |
| 2013 | 575 |
| 2014 | 852 |
| 2015 | 1,499 |
| 2016 | 2,240 |
| 2017 | 2,841 |
| 2018 | 4,387 |
| 2019 | 4,417 |
| 2020 | 3,536 |
| 2021 | 1,917 |
| 2022 | 1,690 |
| 2023 | 1,473 |
| 2024 | 2,271 |
| 2025 | 1,098 |
| 2026 | 1,191 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,023,910 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| endophthalmitisSignal | 1,341 | 199.8 | 188.3 | 205,962 |
| blindness transientSignal | 977 | 106.0 | 99.2 | 88,123 |
| eye inflammationSignal | 924 | 74.4 | 69.6 | 60,432 |
| vitreous floatersSignal | 780 | 59.9 | 55.7 | 41,523 |
| blindness unilateralSignal | 1,048 | 55.7 | 52.4 | 52,135 |
| eye haemorrhageSignal | 798 | 44.2 | 41.1 | 31,632 |
| visual acuity reducedSignal | 1,236 | 26.8 | 25.4 | 29,625 |
| blindnessSignal | 1,437 | 25.4 | 24.1 | 32,513 |
| eye painSignal | 1,162 | 14.6 | 13.8 | 14,444 |
| visual impairmentSignal | 2,037 | 11.6 | 11.1 | 19,519 |
| deathSignal | 7,876 | 6.4 | 6.3 | 37,118 |
| vision blurredSignal | 1,149 | 5.9 | 5.5 | 4,617 |
| product dose omission issueSignal | 1,106 | 2.6 | 2.5 | 1,119 |
| off label use | 1,631 | 1.3 | 1.2 | 114 |
| drug ineffective | 1,188 | 0.6 | 0.6 | 282 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.